Supplementary materials (8).docx (86.5 kB)

Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers - Supplementary materials

figure

posted on 2022-08-22, 08:56 authored by Kangho Suh, Josh J Carlson, Fang Xia, Todd Williamson, Sean D Sullivan

eFigure 1. One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in colorectal cancer

eFigure 2. One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in soft tissue sarcoma

eTable 1. Sensitivity analysis fitting an exponential curve through the median points for progression-free and overall survival for entrectinib

Funding

Bayer US LLC, (Grant / Award Number:)

History

Usage metrics

Categories

Oncology and carcinogenesis not elsewhere classified

Keywords

comparative effectiveness research oncology outcomes research

Licence

CC BY-NC-ND 4.0

Exports